CXCR4在乳腺癌中的表达及意义  

Expression and Significance of CXCR4 Receptor in Human Breast Cancer

作　　者：安松林[1] 于泳[2] 刘君[2] 方志沂[2] 臧凤林[2] 肖绪琪[2] 

机构地区：[1]北京中医药大学东直门医院普外科,北京100700 [2]天津医科大学附属肿瘤医院乳腺中心

出　　处：《中国中西医结合外科杂志》2009年第4期360-363,共4页Chinese Journal of Surgery of Integrated Traditional and Western Medicine

摘　　要：目的:研究CXCR4在人乳腺癌及癌前病变中的表达情况,并分析其与乳腺癌相关临床病理指标之间的关系。方法:采用免疫组织化学方法(IHC)研究CXCR4在23例乳腺导管上皮增生,26例重度不典型导管上皮增生,34例乳腺导管内癌(DCIS)和126例浸润性乳腺癌组织中的表达差异情况;分析浸润性乳腺癌中CXCR4表达与腋窝淋巴结受累数目、临床分期、肿瘤直径、组织学分级等临床病理指标的相关性。结果:CXCR4在乳腺导管上皮增生、重度不典型导管上皮增生、乳腺导管内癌、浸润性乳腺癌组织中的阳性表达率依次为8.70%、23.08%、56.25%、60.32%,表达水平呈现增高趋势,具有随病变恶性程度加重而逐步增高的趋势(P<0.05);但导管内癌和浸润性乳腺癌两组表达水平无明显差别。CXCR4在浸润性乳腺癌中的表达与腋窝淋巴结受累数目、临床分期呈正相关,与肿瘤直径、组织学分级无明显相关性。淋巴结阳性组浸润性乳腺癌CX-CR4阳性表达率高于淋巴结阴性组(P<0.05)。结论:CXCR4可能是乳腺癌发生的早期分子事件;CXCR4在浸润性乳腺癌中的表达与乳腺癌进展的临床病理指标相关,可作为乳腺癌的诊断指标;CXCR4可能成为乳腺癌治疗的新靶点。Diagnosis and Surgical Treatment of 120 Cases of Thyroid Cancer Wang Tao, Fu Qiang, Liu Tong, et al. Insti- tute of General Surgery, Tianjin General Hospital, Tianjin Medical University, Tianjin （300052）, China Abstract：Objective To study the diagnosis and surgical treatment of thyroid carcinoma. Methods Local mass excision was performed in 32 patients, subtotal lobectomy in 19 patients, lobectomy in 19 patients, unilateral lobectomy plus isthmusectomy in 33 patients, near- total thyroidectomy in 12 patients, total thyroidectomy in 5 patients, and at the same time, cervical lymph node dissection was done in 37 cases, and 40 cases had secondary surgery. Results There was no operative mortality, but postoperative hoarseness in five cases, and hand and foot numbness in three cases, choking water in one, and liver metastases after 2 years in another one. Conclusion In case of thyroid masses, all the available information of history, physical examination, ultrasonic inspection, CT, ECT and fine needle aspiration cytology should be carefully analyzed. Under the circumstance of highly malignancy - suspected cases, intraopcrative frozen sec-tion should be done if possible. The operation procedure should be individualized in light of the lesion pathology, by TNM

关 键 词：趋化因子受体CXCR4 乳腺癌 病理指标 转移 

分 类 号：R736.1[医药卫生—肿瘤]